Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 145Parkinson Disease 4, Autosomal Dominant Lewy Body 120Melanoma 84Squamous Cell Carcinoma of Head and Neck 56Neoplasms 44Breast Neoplasms 41Stomach Neoplasms 39Colorectal Neoplasms 38Triple Negative Breast Neoplasms 37Neoplasm Metastasis 36Carcinoma, Renal Cell 36Ovarian Neoplasms 30Lung Neoplasms 30Head and Neck Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Transitional Cell 26Carcinoma, Hepatocellular 26Pancreatic Neoplasms 23Esophageal Neoplasms 20Endometrial Neoplasms 16Recurrence 15Prostatic Neoplasms 15Multiple Myeloma 15Fallopian Tube Neoplasms 15Carcinoma 14Sarcoma 13Lymphoma, Large B-Cell, Diffuse 13Small Cell Lung Carcinoma 12Lymphoma, Follicular 12Lymphoma, Non-Hodgkin 11

Interventions

Gemcitabine 5Paclitaxel 4Nivolumab 3cobimetinib 2atezolizumab 2adavosertib 2Ramucirumab 2N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 2Carboplatin 2zansecimab 1tocilizumab 1tivozanib 1tislelizumab 1temsirolimus 1ridaforolimus 1plocabulin 1pexidartinib 1pevonedistat 1pembrolizumab 1pamiparib 1obinutuzumab 1necitumumab 1liposomal doxorubicin 1lenvatinib 1glasdegib 1futuximab 1demplatin pegraglumer 1birinapant 1avelumab 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Tumors × pembrolizumab × Clear all
NCT02587962 2021-01-14

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Medivir

Phase 1/2 Terminated
34 enrolled 27 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡